The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...
First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of ...
Combination of estramustine, paclitaxel, and tegafur-uracil (ETU) in patients with metastatic hormone-refractory prostate cancer (mHRPC): Efficacy and safety results of a multicenter phase II study No ...
Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...
Effect of loss of a chromosome 7 containing multiple copies of EGFR gene on acquired resistance to EGFR-TKIs in EGFR mutated NSCLC. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I ...
The firm began a Phase II study of evorpacept in HER2-positive breast cancer patients and began testing a higher dose of ALX2004 in a separate Phase I trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback